Senores Pharmaceuticals Ltd (SENORES) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039497, "name": "Senores Pharma.", "stock_name": "Senores Pharma.", "full_name": "Senores Pharmaceuticals Ltd", "name_url": "stocks-analysis/senores-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "736.70", "chg": 9.6, "chgp": "1.32%", "dir": 1, "prev_price": "727.10", "mcapval": "3,392.77 Cr", "mcap": "Small Cap", "scripcode": "544319", "symbol": "SENORES", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE0RB801010", "curr_date": "Mar 16", "curr_time": "", "bse_nse_vol": "83.11 k", "exc_status": "Active", "traded_date": "Mar 16, 2026", "traded_date_str": "2026 03 16", "score": "", "scoreText": "", "Live": 0, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/senores-pharma-10039497-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3877839", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SenoresPharmace_mojoScore_3877839.png", "date": "2026-03-07 10:10:27", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Senores Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicators", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicators-3868454", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SenoresPharmace_technicaldot_3868454.png", "date": "2026-03-04 08:08:18", "description": "Senores Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a modest daily price decline, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential resilience in the near term." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3852826", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SenoresPharmace_mojoScore_3852826.png", "date": "2026-02-24 10:10:04", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3834972", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SenoresPharmace_mojoScore_3834972.png", "date": "2026-02-12 10:10:03", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 February 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3814203", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SenoresPharmace_mojoScore_3814203.png", "date": "2026-02-01 10:10:04", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 November 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Senores Pharmaceuticals Gains 1.40%: 4 Key Factors Driving the Week’s Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-gains-140-4-key-factors-driving-the-weeks-moves-3802809", "imagepath": "", "date": "2026-01-24 09:00:07", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 19:</strong> Stock opens strong at Rs.806.55 (+2.06%) despite Sensex decline</p>\n <p><strong>Jan 20:</strong> Q3 FY26 results reveal robust growth but stock dips 2.90%</p>\n <p><strong>Jan 21:</strong> Intraday high of Rs.838.60 with 7.13% surge on strong financial trend</p>\n <p><strong>Jan 22:</strong> Quality grade upgraded amid strong fundamentals</p>\n <p><strong>Jan 23:</strong> Week closes at Rs.801.30, down 4.29% on profit booking</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-va..." }, { "title": "Senores Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-upgrades-quality-grade-amid-strong-financial-performance-3799439", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_qualitydot_3799439.png", "date": "2026-01-22 08:00:12", "description": "Senores Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. The company’s robust sales and EBIT growth, alongside prudent debt management and enhanced returns on capital, underpin this positive reassessment by MarketsMOJO. Investors should consider these developments in the context of the broader pharmaceuticals sector and Senores’ recent market performance." }, { "title": "Senores Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-hold-3798108", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_mojoScore_3798108.png", "date": "2026-01-21 10:10:53", "description": "Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook." }, { "title": "Senores Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Trend Amid Market Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-reports-very-positive-quarterly-financial-trend-amid-market-volatility-3797532", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SenoresPharmace_fintrenddot_3797532.png", "date": "2026-01-21 08:00:12", "description": "Senores Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a shift from an outstanding to a very positive financial trend. Despite recent market headwinds and a 2.9% decline in share price on 21 Jan 2026, the company’s robust revenue growth and margin expansion underscore its strengthening fundamentals within the Pharmaceuticals & Biotechnology sector." } ], "total": 180, "sid": "10039497", "stock_news_url": "https://www.marketsmojo.com/news/senores-pharmaceuticals-10039497" }, "announcements": "", "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Jan 19: Stock opens strong at Rs.806.55 (+2.06%) despite Sensex decline

Jan 20: Q3 FY26 results reveal robust growth but stock dips 2.90%

Jan 21: Intraday high of Rs.838.60 with 7.13% surge on strong financial trend

Jan 22: Quality grade upgraded amid strong fundamentals

Jan 23: Week closes at Rs.801.30, down 4.29% on profit booking

Week Open

Read full news article

Senores Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Performance

2026-01-22 08:00:12

Senores Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. The company’s robust sales and EBIT growth, alongside prudent debt management and enhanced returns on capital, underpin this positive reassessment by MarketsMOJO. Investors should consider these developments in the context of the broader pharmaceuticals sector and Senores’ recent market performance.

Read full news article

Senores Pharmaceuticals Ltd is Rated Hold

2026-01-21 10:10:53

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Read full news article

Senores Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Trend Amid Market Volatility

2026-01-21 08:00:12

Senores Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a shift from an outstanding to a very positive financial trend. Despite recent market headwinds and a 2.9% decline in share price on 21 Jan 2026, the company’s robust revenue growth and margin expansion underscore its strengthening fundamentals within the Pharmaceuticals & Biotechnology sector.

Read full news article